683 Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

683 Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$14.1M	Buy	782,500 +32,500	+4%	+$615K	0.69%	34
2026 Q1	$16.3M	Sell	750,000 -60,000	-7%	-$1.16M	0.85%	27
2025 Q4	$17.4M	Sell	810,000 -180,000	-18%	-$3.79M	0.76%	29
2025 Q3	$19.1M	Buy	990,000 +315,000	+47%	+$5.62M	1%	27
2025 Q2	$11.5M	Buy	675,000 +510,000	+309%	+$21.8M	0.76%	36
2025 Q1	$10.5M	Buy	165,000 +63,000	+62%	+$6.63M	0.73%	37
2024 Q4	$12.4M	Buy	102,000 +14,778	+17%	+$1.81M	0.77%	33
2024 Q3	$10.9M	Buy	87,222 +23,722	+37%	+$3.28M	0.83%	35
2024 Q2	$10M	Buy	63,500 +671	+1%	+$86.2K	0.76%	41
2024 Q1	$8.13M	Sell	62,829 -23,771	-27%	-$2.91M	0.6%	48
2023 Q4	$8.35M	Buy	86,600 +66,600	+333%	+$6.39M	0.68%	49
2023 Q3	$2.42M	Sell	20,000 -10,600	-35%	-$1.2M	0.19%	81
2023 Q2	$3.5M	Buy	+30,600	New	+$3.95M	0.25%	82

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

683 Capital Management's SRPT Position: Q2 2026 in Review

683 Capital Management increased its Sarepta Therapeutics (SRPT) stake by 4.3% in Q2 2026, buying an estimated $615K and bringing the position to 782,500 shares worth $14.1M. The position accounts for 0.69% of the portfolio, ranked #34.

683 Capital Management first reported a position in SRPT in Q2 2023 and has held it in 13 quarters since. The position peaked at $19.1M in Q3 2025. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

683 Capital Management held 782,500 shares of Sarepta Therapeutics worth $14.1M as of Q2 2026.
683 Capital Management bought 32,500 Sarepta Therapeutics shares in Q2 2026, an estimated $615K.
Sarepta Therapeutics made up 0.69% of 683 Capital Management's portfolio in Q2 2026, its #34 holding.
683 Capital Management first reported a position in Sarepta Therapeutics in Q2 2023 and has held it in 13 quarters since.
683 Capital Management's Sarepta Therapeutics position peaked at $19.1M in Q3 2025.
323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on 683 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.